JAMA Cardiology

AUGUST 13, 2024

This randomized clinical trial investigates the effects of verinurad on exercise capacity and symptoms in patients with heart failure with preserved ejection fraction (HFpEF) and elevated serum uric acid levels.

Preserved Ejection Fraction 72

Preserved Ejection Fraction Exercise Heart Failure 72

JAMA Cardiology

MARCH 11, 2025

This randomized clinical trial evaluates if HU6, a controlled metabolic accelerator, reduces body weight, improves body composition, and increases exercise capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 72

Preserved Ejection Fraction Obesity Exercise Heart Failure 72

Circulation: Heart Failure

DECEMBER 6, 2024

Circulation: Heart Failure, Ahead of Print. BACKGROUND:In heart failure, sympathetic excess and exercise intolerance impair quality of life. CONCLUSIONS:In contrast to CMCs, patients with HFpEF exhibit augmented MSNA at rest and during exercise.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Exercise Heart Failure Quality of Life 40

Circulation: Heart Failure

OCTOBER 23, 2023

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010633, November 1, 2023. BACKGROUND:Heart failure with preserved ejection fraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Biomarkers Exercise 40

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Pulmonary vascular resistance at rest and exercise decreased with higher BMI.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

European Journal of Heart Failure

DECEMBER 28, 2023

Abstract Aims Preventive strategies for heart failure (HF) with preserved ejection fraction (HFpEF) include pharmacotherapies and lifestyle modifications. Thus, we evaluated the association between CRF and HFpEF incidence.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Article 40

Journal of the American Heart Association

DECEMBER 29, 2023

Journal of the American Heart Association, Ahead of Print. BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), and it is a strong predictor of adverse outcomes.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Pulmonary Heart Failure Hypertension 40

Heart BMJ

FEBRUARY 12, 2024

Learning objectives To understand the importance of exercise and physical activity in the general management and well-being of people with heart failure (HF). To understand the key principles of exercise training prescription in people with HF. cross-ref type="bib".

Exercise 40

Exercise Heart Failure Preserved Ejection Fraction Pharmacology 40

Journal of the American Heart Association

FEBRUARY 14, 2024

Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).We Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).We

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Blood Pressure Biomarkers 40

DAIC

APRIL 22, 2024

RELIEVE-HF failed to meet its primary efficacy endpoint and did not reduce heart failure events or improve quality of life in heart failure patients with a preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 105

Preserved Ejection Fraction Quality of Life Heart Failure Pacemaker 105

Circulation: Heart Failure

DECEMBER 1, 2023

Circulation: Heart Failure, Ahead of Print.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Exercise Circulation 40

Journal of the American Heart Association

MARCH 3, 2025

Journal of the American Heart Association, Ahead of Print.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Exercise 40

Circulation: Heart Failure

SEPTEMBER 12, 2023

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010618, November 1, 2023. BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear. mL/kg per min lower peak VO2(β, −2.35±0.19;P<0.001).

Biomarkers 40

Biomarkers Obesity Exercise Preserved Ejection Fraction 40

The American Journal of Cardiology

FEBRUARY 8, 2024

Publication date: Available online 7 February 2024 Source: The American Journal of Cardiology Author(s): Lajjaben Patel, Matthew W Segar, Neil Keshvani, Vinayak Subramanian, Ambarish Pandey, Alvin Chandra

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Exercise 40

Circulation: Heart Failure

DECEMBER 18, 2023

Circulation: Heart Failure, Volume 16, Issue 12 , Page e010673, December 1, 2023. BACKGROUND:Twitch-independent tension has been demonstrated in cardiomyocytes, but its role in heart failure (HF) is unclear. mm Hg with exercise (P<0.001). mm Hg with exercise (P<0.001). mm Hg, increasing to 18.5

Preserved Ejection Fraction 40

Preserved Ejection Fraction Exercise Cardiomyopathy Heart Failure 40

JAMA Cardiology

JULY 23, 2024

Among patients with heart failure with preserved ejection fraction (HFpEF), right ventricular (RV) dysfunction is strongly associated with an increased risk of morbidity and mortality.

Preserved Ejection Fraction 42

Preserved Ejection Fraction Heart Failure Pulmonary Exercise 42

DAIC

APRIL 3, 2024

Featured topics will include in-depth sessions covering non-statin lipid lowering therapies, heart failure with preserved ejection fraction, viability, imaging modalities for the assessment of coronary artery disease, and antiplatelet therapy after coronary stenting.

Education 105

Education Preserved Ejection Fraction Coronary Artery Disease Cardio Oncology 105

Circulation

DECEMBER 21, 2023

BACKGROUND:Metabolic distress is often associated with heart failure with preserved ejection fraction (HFpEF) and represents a therapeutic challenge. Circulation, Ahead of Print. Metabolism-induced systemic inflammation links comorbidities with HFpEF.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Diet Exercise Heart Failure 45

Circulation

NOVEMBER 11, 2024

Introduction:Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure which is rapidly rising in incidence in the US today. After 5 weeks of the diet, HFD mice and their littermate controls underwent baseline exercise testing and echocardiograms.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Echocardiogram Exercise Diet 40

Circulation

NOVEMBER 11, 2024

Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. HFD/L-NAME mice showed altered exercise capacity (p<0.05

Hypertension 40

Hypertension Preserved Ejection Fraction Blood Pressure Obesity 40

Dr. S. Venkatesan MD

APRIL 18, 2024

Lowering the raised LA mean pressure is a major therapeutic goal in any severely symptomatic left heart disease, whether it is valvular or myocardial disease. It is prudent to understand, that even in systolic LV failure; it is the raised LVEDP that causes the symptoms and marks the limits of exercise capacity. JAMA Cardiol.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Pulmonary Congenital Heart Disease VSD 40

DAIC

FEBRUARY 29, 2024

ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, (..)

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

Circulation

DECEMBER 7, 2023

BACKGROUND:Sodium-glucose cotransporter 2 inhibitors reduce the risk of worsening heart failure (HF) and cardiovascular death in patients with HF irrespective of left ventricular ejection fraction. Dapagliflozin did not improve these outcomes in patients with HF with preserved ejection fraction.

Preserved Ejection Fraction 84

Preserved Ejection Fraction Heart Failure Exercise Cardiomyopathy 84

European Journal of Heart Failure

NOVEMBER 19, 2024

Muscle quality and cardiac function in heart failure with preserved ejection fraction (HFpEF) during exercise. Therefore, the study aimed to determine the relationship between locomotor MQ and cardiac function during exercise in HFpEF. MQ was calculated as peak watts divided by LL%. vs. 2.3 ± 0.6 W/%,

Preserved Ejection Fraction 40

Preserved Ejection Fraction Cardiac Function Exercise Heart Failure 40

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

European Journal of Heart Failure

DECEMBER 13, 2023

Venn diagram highlighting the main similarities and differences between heart failure with preserved ejection fraction (HFpEF) and aortic stenosis with preserved ejection fraction (ASpEF). HFpEF and ASpEF patients showed similar demographic distribution and biohumoral profiles. vs. controls).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Stenosis Heart Failure Aortic 40

European Journal of Heart Failure

DECEMBER 7, 2023

ABSTRACT Background Left atrial (LA) myopathy is increasingly recognized as an important phenotypic trait in heart failure (HF) with preserved ejection fraction (HFpEF). There were 94 patients with events over a median follow-up of 2.9 (IQR 2.92, p = 0.01). 2.92, p = 0.01).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Exercise Tricuspid 40

European Journal of Heart Failure

FEBRUARY 5, 2025

Beta-blockers are commonly used in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Methods and results We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Outcomes Atrial Fibrillation 40

Circulation

NOVEMBER 17, 2024

Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. 6MWD 302.881.7meters, and 53%(n=388) had a worsening heart failure event in the prior 12 months. points (95%CI, 3.3,

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Obesity Quality of Life 40

European Journal of Heart Failure

DECEMBER 29, 2023

Abstract Aims We aim to clarify the extent to which cardiac and peripheral impairments to oxygen delivery and utilization contribute to exercise intolerance and risk for adverse events, and how this relates to diversity and multiplicity in pathophysiological traits. Hemodynamics and oxygen transport responses were compared. L/min versus 2.8

Preserved Ejection Fraction 40

Preserved Ejection Fraction Exercise Heart Failure Pulmonary 40

Circulation

NOVEMBER 11, 2023

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. mg improved symptoms, physical limitations and exercise function, and reduced inflammation and body weight.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Quality of Life Obesity Heart Failure 40

Circulation

NOVEMBER 11, 2024

The primary outcomes were exercise capacity, diastolic function, and quality of life at baseline evaluation. After controlling for potential confounding variables, there were no differences in baseline exercise capacity [peak VO2 (mL/kg/min): 12.1 Patients were divided into two groups based on BB use at trial enrollment.

Quality of Life 40

Quality of Life Preserved Ejection Fraction Exercise Heart Failure 40

DAIC

JUNE 26, 2024

Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

International Journal of Cardiovascular Sciences

OCTOBER 21, 2024

Santos Most Cited Article – Reduction in Hospitalization and Increase in Mortality Due to Cardiovascular Diseases during the COVID-19 Pandemic in Brazil Authors: Paulo Garcia Normando, José de Arimatéia Araujo-Filho, Gabriela de Alcântara Fonseca, Rodrigo Elton Ferreira Rodrigues, Victor Agripino Oliveira, Ludhmila Abrahão Hajjar, André Luiz (..)

Article 52

Article Preserved Ejection Fraction COVID-19 Heart Failure 52

DAIC

APRIL 9, 2024

Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. The study was funded by Imbria Pharmaceuticals, developer of ninerafaxstat.

Cardiomyopathy 52

Cardiomyopathy Quality of Life Chest Pain Preserved Ejection Fraction 52